Sero-epidemiology and associated factors of HIV, HBV, HCV and syphilis among blood donors in Ethiopia: a systematic review and meta-analysis

Mulugeta Melku1*, Sintayehu Ambachew2, Bamlaku Enawgaw1, Molla Abebe2, Zegeye Abebe3, Tekalign Deressa4,5, Debasu Damtie5, Belete Biadgo2, Belay Tessema6, Demeke Geremew5, Asemarie Kebede7, Berhanu Woldu1, Takele Teklu5 and Elias Shiferaw1

Abstract

Background: Transfusion transmissible infections (TTIs) remain a major public health problem in developing countries including Ethiopia. In Ethiopia, comprehensive information about sero-epidemiology of major TTIs is lacking at the national level. Therefore, this systematic review and meta-analysis was aimed at providing the pooled estimate of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis among blood donors in Ethiopia.

Methods: Relevant studies published until May 31, 2019 were searched through PubMed/Medline, EMBASE, SCOPUS, HINARI, Cochrane database library, Web of Science, Google Scholar and Google. The methodological quality of articles was assessed using Joanna Briggs Institute critical appraisal checklist for prevalence and analytical studies. The pooled sero-epidemiology of HIV, HBV, HCV and syphilis were determined using the random-effects model. Heterogeneity between the studies was assessed using the I² statistics. Publication bias was assessed by visual inspection of the funnel plot and Egger’s statistics.

Results: A total of 7921 articles were retrieved, and 7798 were screened for eligibility after duplicates removed. Forty-nine full-text articles were assessed for eligibility; of which 45 were eligible for qualitative and quantitative synthesis: categorized as 36, 34, 31 and 23 studies for estimations of HBV, HIV, HCV and syphilis, respectively. In the random-effects model, the pooled sero-epidemiology of HBV, HIV, HCV and syphilis was 5.20, 2.83, 0.93 and 1.50%, respectively. Moreover, being a male blood donor was significantly associated with HBV and syphilis infection, whereas being a replacement blood donor was significantly associated with a high burden of HIV, HBV and HCV infections.

Conclusion: The pooled sero-epidemiology of major TTIs among blood donors was high. Therefore, there is a need to design prevention and control strategies in a comprehensive approach to reduce the burden.

Keywords: Blood donors, Ethiopia, Meta-analysis, Sero-epidemiology, Systematic review, Transfusion-transmissible Infections

*Correspondence: mulugeta.melku@gmail.com
1 Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
Full list of author information is available at the end of the article

Background

Blood is an invaluable, life-sustaining fluid. The loss of a large volume of blood due to casualties, hemorrhage, and other medical conditions lead to blood transfusion as
part of the standard care to save a life. Because of this, blood transfusion is considered as an integral and essential element of a health care system [1, 2]. Though blood transfusion is one of the ways to save patients’ life in many cases, sometimes it poses the risk of TTIs. Supplying safe blood and preventing the transmission of infectious diseases are among the utmost important goals for blood transfusion organization [1]. Transfusion-transmissible infectious agents mainly HIV, HBV, HCV, and syphilis are among the greatest threats for the receivers if not rigorously screened [3].

According to the World Health Organization (WHO) 2016 report, the reactivity for markers of TTIs, outdated stock, and incomplete collection were the main reasons for the discard of donated blood. The median total discard rate was 10.9, 9.0, 6.7 and 5.7% in lower-middle-income, low-income, upper-middle-income, and high-income countries, respectively. Markers of TTIs are the most common reason for the discard, which accounted for a median discard rate of 7.4, 5.1, 3.9 and 1.1% in low-income, lower-middle-income, upper-middle-income, and high-income countries, respectively. Globally, it is estimated that 1.8 million donated blood were discarded due to TTIs reactivity in 2013 [4].

On another hand, according to the WHO report of 2020, 37.6 million people were living with HIV globally, with over two-thirds of who are living in the WHO African region. Some portion of HIV infection was through transfusion of blood and blood products. Similarly, reports from Sub-Saharan Africa showed that the median overall risk of becoming infected with HIV from a blood transfusion is 1 infection per 1000 units [5], and risk for 12.5% of post-transfusion viral hepatitis infection [6].

Viral hepatitis is the other global health burden. More than one million people die each year from HCV and HBV infections. According to the WHO 2017 report, chronic HBV infection affects over 257 million people worldwide. On the other hand, HCV is a leading cause of chronic liver disease, and persistent HCV infection is associated with cirrhosis, hepatocellular carcinoma, liver failure, and death [7]. Globally, the sero-prevalence of HCV ranges from 2 to 3%, with an estimated 71.1 million patients with active viremia, where 10.15 million are from sub-Saharan Africa [8]. Recent systematic review and meta-analysis showed that HCV was estimated to be 1.78% among blood donors in sub-Saharan Africa [9]. On the other hand, syphilis was also associated with blood donation, and its sero-prevalence among blood donors varies in Africa [10–13].

Implementing rigorous screening algorithm of donated blood and blood products for markers of TTIs is the strategy to ensure the safety of blood donation. However, the risk of post-transfusion hepatitis and HIV is challenging in Sub-Saharan African countries; and patients who received blood transfusion develop post-transfusion hepatitis and HIV [5, 6]. Therefore, prevention and control of TTIs is the leading concern and priority agenda of WHO in Sub-Saharan Africa [14] and also the Ethiopian Federal Ministry of Health [15].

Systematic review and meta-analysis generates pooled and concrete evidence that would help to determine the distribution of the TTIs and contributes to planning the national strategies for containment and awareness-raising campaigns as well as to design specific preventive measures. As to the authors’ knowledge, limited systematic and meta-analysis were reported, each focusing on a single TTI type [16, 17]. Thus, systematically organized and strong evidence with regard to the sero-epidemiology and associated factors of the major TTIs among blood donors in Ethiopia is crucial. Therefore, the aim of this review was to estimate the epidemiology of TTIs among blood donors in Ethiopia by: (a) performing a systematic literature review, and (b) performing a meta-analysis on TTIs sero-prevalence and commonly reported risk factors of TTIs.

Methods

Context of the review

The context of this systematic review was limited to blood donors in Ethiopia. Ethiopia is one of the developing countries located in the sub-Saharan and horn of Africa having more 100 million people with an area of 1,100,000 km².

Design and protocol registration

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P 2015 Guidelines) was used for this review [18]. The protocol had been registered in the PROSPERO with a registration number CRD42018076616.

Eligibility criteria

Primary studies with full-text original articles written in English up to May 31, 2019 and having extractable data on sero-epidemiology of and/or factors associated with HIV, HBV, HCV and syphilis among blood donors in Ethiopia were included in the review. However, studies conducted among Ethiopian blood donors living abroad, repeated studies used the same dataset, and studies focused on the molecular Epidemiology of TTIs, case-control studies, case reports, case series and editorials were excluded from this review.

Outcomes of the review

This review had two outcomes. The first outcome was to determine the pooled sero-epidemiology of HIV, HBV,
HCV and syphilis among blood donors in Ethiopia. The secondary outcome was to identify factors associated with the sero-epidemiology HBV, HIV, HCV and syphilis.

Search strategy
All relevant articles published were searched in PubMed/Medline, EMBASE, HINARI, SCOPUS, Cochrane database library, Google Scholar and Web of Sciences electronic databases. In addition, we searched grey literature in Google. The search terms were developed in accordance with the Medical Subject Headings Thesaurus (MeSH), and Boolean operators (AND, OR) were used for searching the articles. The following terms in combination with free text key terms; “transfusion transmissible infections”, “transfusion transmissible diseases”, “transfusion transmissible viral hepatitis”, “Transfusion transmitted infections”, “Transfusion transmitted viral hepatitis”, “HIV”, “Hepatitis B virus”, “TTIs” “Hepatitis C virus” “Syphilis”, “T.pallidum”, “blood donor” and “Ethiopia” were used. Also, hand searching of articles published in the Ethiopian Journal of Health Sciences, Ethiopian Medical Journal, Ethiopian Journal of Health and Development, and Ethiopian Journal of Health and Biomedical Sciences was conducted. Reference lists of relevant retrieved articles were used to identify any studies that were not retrieved through electronic database searching.

Study selection and quality appraisal
First, retrieved articles were imported to EndNote X7 (Thomson Reuters, New York, USA), and duplicated articles were removed electronically, and manually if the citation style variation of different databases were noted. Then, articles were screened by their title and abstract independently by two groups comprising four authors each: group one (MM, ZA, MA, BB), and group two (SA, ES, BW, DG). Similarly, the two groups of authors had appraised the full-texts of the studies and in case of discrepancies, it was resolved by the third group of authors (BE, BT, TD, DD, TT, AK). In the case of articles eligible for full-text appraisal but not accessible in full text, the corresponding author communicated with the journal editorial office and/or publishers via email and/or phone. For assessment of the methodological quality of articles, the Joanna Briggs’s Institute critical appraisal tools for prevalence and analytical studies were used [19, 20].

Data extraction
The data were extracted using Microsoft Excel format. Accordingly, the following pieces of information were collected: first author’s name, year of publication, year of data collection, length of the data collection period, sampling techniques (blood donors recruitment strategy), a diagnostic method used, total population participated, the number of blood donors who were sero-reactive for HIV, HBV, HCV and syphilis, blood donors type, median/mean age of the study participants, sex of study participants, and the number of male and female blood donors who were sero-reactive and non-reactive, sero-reactivity for each TTIs by donor type, and the reported odds ratio (OR) for the respective TTIs.

Data analysis and interpretation
We used STATA version 14 software (Stata Corp LLC, Texas, USA) for analysis. The magnitude of heterogeneity between included studies was quantitatively measured by the index of heterogeneity ($I^2$ statistics) [21]. Low, medium and high heterogeneities were noted where the $I^2$ values are 25%, 50% and 75%, respectively. The significance of heterogeneity was determined by the P-value of $I^2$ statistics and a P-value of <0.05 was considered as evidence of heterogeneity. In the case of a medium and high level of heterogeneity between the included studies, Dersimonian and Laird random-effects model [22], sensitivity and subgroup analysis were used for estimating the pooled effect size. Considering the median year of sample collection as a factor, univariable random-effects meta-regression was performed to evaluate the trend of TTIs sero-prevalence over time.

Similarly, small-study effect or publication bias was evaluated using the visual funnel plot test, and Egger’s statistics. In the case of small-study effect, trim and fill analysis (Duval and Tweedie’s methods) was used to adjust the pooled estimates [23]. The ORs were extracted from the articles when reported, or calculated for each of the reported variables and pooled in a meta-analysis. Then OR with its 95% confidence interval was used to estimate the association between each TTIs and the reported factors. The results were presented using text and plots.

Results
Characteristics of included studies
A total of 7921 records were retrieved; of which 123 articles were removed due to duplication. During title/abstract screening, 7749 articles were also removed as their titles and abstracts were not relevant to the current review. One article eligible for full-text appraisal was excluded as the full-text article was not accessible after repeated contact of the corresponding author via email, and the journal editorial office [24]. The remaining 49 full-text articles were assessed for eligibility.

Out of the total studies that underwent critical appraisal, 4 were excluded: 1 study did not report the epidemiology HBV infection [25]; 1 study the sample size is too small for epidemiological estimation [26]; 1 study did not clearly report the outcome interest [27], and the
other study authored by Dessie et al. in 2008 [28] was a duplicate publication from the same dataset published in 2007 [29]. The remaining 45 studies were included in the qualitative and quantitative synthesis (Fig. 1).

Regarding the type of literature included in this review, 43 (95.6%) articles were published studies, and the rest were grey literature [30, 31], which involved a total 4,441,920 study participants. Twenty-four (53.3%) and 21 (46.7%) of the included studies were retrospective and prospective studies, respectively. Concerning the regions where these studies conducted, 17 (37.8%), 6 (13.3%), 6 (13.3%) and 5 (11.1%) of the studies were conducted in Amhara, Addis Ababa, South Nations and Nationalities, and Oromia regional state, respectively; whereas 4 (8.9%) of the studies were sub-national level studies.

Of all included studies, 36 reported HBV [3, 13, 29–62]; 34 reported HIV [3, 13, 29–33, 35–38, 42, 43, 45, 46, 48–58, 60–68]; 31 reported HCV [3, 13, 29–33, 35–38, 41–43, 45–51, 54, 55, 57, 58, 60–62, 69, 70]; and 23 reported syphilis [3, 13, 29–31, 33, 35, 36, 38, 42, 43, 45, 46, 49–52, 54, 57, 58, 60, 68, 71] prevalence among blood donors in Ethiopia. Regarding the distribution of each TTI with sex and donor type of the study participants, it was found as follows: of 36 studies reported HBV, 24 and 9 reported sex and donor type, respectively; of 34 studies reported HIV, 24 and 8 studies reported sex and donor type, respectively; of 31 reported HCV, 19 and 7 reported sex and donor type, respectively; and of 23 studies reported syphilis, 14 and 5 studies reported sex and donor type, respectively (Table 1).

![Fig. 1](image-url)
## Table 1: Characteristics of studies included in the systematic review and meta-analysis of TTIs among blood donors in Ethiopia

| First Author          | Publication year | Sampling year | Study Design | Blood donor type | Setting       | Sample Size | Blood donor by sex | HIV reactive | HIV Diagnosis method | HBV reactive | HBVSAg reactive | HBVSAg Diagnosis method | Anti-HCV reactive | Anti-HCV Diagnosis Method | HCV reactive | HCV Diagnosis Method | Syphilis reactive | Syphilis Diagnosis Method |
|-----------------------|------------------|---------------|--------------|------------------|---------------|-------------|-------------------|--------------|----------------------|--------------|-------------------|-----------------------------|----------------|--------------------------|----------------|----------------------|-----------------|------------------------|
| Asrie F et al. 2016   | 2015             | Prospective   | Both         | North Gondar     | 558           | 351         | Male              | 1.4% (8/558) | 4th Gen ELISA         | 4.9% (22/558) | 3.9% (27/558) | 3.9% (27/558) ELISA                                | 1.8% (10/558) | 4th Gen ELISA                           |   |   |   |
| Teklemariam Z, et al. | 2008–2015        | Retrospective | Both Harar    | 11,382           | 9403          | 1978        | Male              | 0.6% (69/11382) | ELISA               | 4.4% (5001/11382)ELISA |   |   |   | 0.8% (91/11382) ELISA                           |   | 1.6% (182/11382) ELISA                       |   |   |   |
| Habe Y et al. 2016    | 2009–2014        | Retrospective | Both Dire Diwa| 4157            | 3454          | 723         | Female             | 3.7% (155/4157) | –                   | –                        | –                   | –                        |   |   |   |
| Sharew B et al. 2017  | 2008–2012        | Retrospective | Both Desie    | 9384            | 7514          | 1870        | Female             | 5.1% (476/9384) | –                   | –                        | –                   | –                        |   |   |   |
| Dresia T et al. 2018  | 2014–2017        | Retrospective | Both North Shewa | 8460           | 5644          | 2816        | Male              | 0.25% (21/8460) | 4th Gen ELISA         | 1.2% (103/8460) | 4th Gen ELISA | 1.2% (103/8460) ELISA                                | 0.32% (27/8460) | ELISA                           |   | 0.71% (60/8460) TPHA   |   |   |   |
| Seyoum E, et al. 2005 | 2003             | Prospective   | Both Addis Ababa | 408            | –             | –           | Male              | 4.2% (17/408)  | –                   | –                        | –                   | –                        |   |   |   | –                   |   | –                        |   |   |   |
| Ambachew H et al. 2018| 2016             | Prospective   | Both Hawassa  | 2237            | –             | –           | Male              | 1.7% (38/2237) | 4th Gen ELISA         | 4.7% (106/2237) | 4th Gen ELISA | 4.7% (106/2237) ELISA                                | 0.5% (11/2237) | ELISA                           |   | 0.5% (11/2237) ELISA   |   |   |   |
| Degesa B et al. 2018  | 2011–2014        | Retrospective | Both Mekelle  | 10,728          | 3750          | 6978        | Male              | 1.03% (111/10728) | 4th Gen ELISA         | 3.8% (407/10728) | 4th Gen ELISA | 3.8% (407/10728) ELISA                                | 1.33% (143/10728) | ELISA                           |   |   |   |
| Abate M et al. 2016   | 2010–2014        | Retrospective | Both Jigiga   | 6827            | 6648          | 179         | Male              | 3.16% (216/6687) | 4th Gen ELISA         | 9.48% (647/6687) | 4th Gen ELISA | 9.48% (647/6687) ELISA                                | 0.73% (50/6827) | ELISA                           |   | 0.73% (50/6827) RPR     |   |   |   |
| Frommel D et al. 1993 | 1991             | Prospective   | Both Addis Ababa | 220            | 133           | 87          | Male              | –                   | 2nd Gen ELISA        | –                        | –                   | 1.4% (3/220) ELISA                                 |   |   |   |
| Gelaw B et al. 2007   | 2002–2003        | Prospective   | Both Amhara & Tigrai | 600          | 578           | 22          | Male              | 6.2% (37/600)  | Immuno-chromatography | 1.7% (10/600) | Immuno-chromatography | 1.7% (10/600) | Immuno-chromatography |   |   |   |
| Gezahegn et al. 2012  | 2007–2010        | Retrospective | Both Jimma    | 3788            | 3034          | 754         | Male              | 1.0% (39/3788) | –                   | –                        | –                   | –                        |   |   |   |
| Hunde GB et al. 2016  | 2013–2014        | Prospective   | Both National | 56,885         | 40,204        | 16,681      | –                 | 3.9% (2217/56885) | 4th Gen ELISA         | 0.52% (294/56885) | –                        | –                   | –                   |   |   |   |
| Kebede W et al. 2017  | 2010–2015        | Retrospective | Both Jimma    | 10,733          | 7068          | 3125        | –                 | 0.2% (23/10733) | 3.05% (328/10733)ELISA | 0.2% (22/10733) | ELISA                           |   | 0.14% (15/10733) ELISA   |   |   |   |
| Yemi A et al. 2011    | 2010             | Retrospective | Both Jimma    | 6,063           | 4802          | 1261        | –                 | 2.1% (129/6063) | ELISA               | 2.1% (126/6063) | ELISA                           |   | 0.7% (44/6063) RPR      |   |   |   |
| First Author            | Publication year | Sampling year | Study Design | Blood donor type | Setting | Sample Size | Blood donor by sex | HIV | HBV | HCV | Syphilis | Anti-HCV reactive | Anti-HCV Diagnosis Method | HIV reactive | HBVsAg reactive | HBVsAg Diagnosis method | Syphilis reactive | Syphilis Diagnosis Method |
|------------------------|------------------|---------------|--------------|------------------|---------|-------------|-------------------|-----|-----|-----|----------|------------------|--------------------------|--------------|------------------|--------------------------|-------------------|--------------------------|
| Tsega E et al.         | 1995             | 1992–1994     | Prospective  | Volunteer        | Addis Ababa | 500          | –                 | –   | –   | –   | –        | –                | ELISA                    | –            | –                | –                        | –                 | –                        |
| Tsega E et al.         | 1987             | 1986          | Prospective  | Volunteer        | Addis Ababa | 459          | 409               | 50  | –   | –   | –        | –                | ELISA                    | –            | –                | –                        | –                 | –                        |
| Tessema B et al.       | 2010             | 2003–2007     | Retrospective | Both             | North Gondar | 6361         | 5592              | 769 | 3.8% (239/6361) | ELISA | 4.7% (298/6361) | –                | –                        | –            | –                | –                        | 0.7% (35/6361) | ELISA                    |
| Terefe JE et al.       | Unpublished      | 2008–2013     | Retrospective | Both             | Addis Ababa  | 173,207      | 135,007           | 38,200 | 6.4% (2848/173207) | ELISA | –                | –                | –                        | –            | –                | –                        | –                 | 1.3% (83/6361) RPR |
| Sisay Y et al.         | 1995             | 1987–1989     | Retrospective | Both             | National     | 19,408       | 16,735            | 2473 | –               | –    | –                | –                | –                        | –            | –                | –                        | –                 | –                        |
| Bifan W et al.         | Unpublished      | 2016–2017     | Prospective  | Volunteer        | Amhara       | 987          | 554               | 433  | 4.0% (4/987)    | 4th Gen ELISA | –                | –                | –                        | –            | –                | –                        | 0.1% (4/987)       | ELISA RPR + TPHA |
| Ataro Z et al.         | 2010–2013        | Prosp ective  | Both          | Dire Dawa        | –            | 6376         | 5430              | 946  | 1.24% (79/6376) | ELISA | –                | –                | –                        | –            | –                | –                        | –                 | –                        |
| Mohammed Y et al.      | 2010–2013        | Retrospective | Both          | Jijiga           | –            | 4224         | 4171              | 53   | 1.0% (6/6424)   | ELISA | 10.9% (40/4224) | –                | –                        | –            | –                | –                        | 0.4% (17/4224)    | ELISA |
| Arose A et al.         | 2007–2008        | Prosp ective  | Both          | Bahir Dar        | –            | 2384         | 2177              | 207  | –               | –                | 4.11% (98/2384) | ELISA | –                | –                        | 0.63% (5/2384)    | ELISA |
| Biadgo B et al.        | 2010–2012        | Retrospective | Both          | North Gondar     | –            | 6741         | 5311              | 1160 | 2.24% (145/6471) | 4th Gen ELISA | 3.6% (233/6471) | 3rd Gen ELISA | 0.8% (5/6471) | 3rd Gen ELISA | –                | –                        | –            | –                | –                        | –                 | –                        |
| Berhansebse M et al.   | 2009–2013        | Retrospective | Both          | Hawassa          | –            | 6306         | 5471              | 835  | 1.6% (101/6300) | 4th Gen ELISA | 4.8% (303/6300) | ELISA | –                | –                        | 0.6% (38/6300)    | ELISA | 0.5% (32/6300) RPR |
| Biteteke FS et al.     | 2015             | Prospective   | Wolaytssodo   | –                | –            | 390          | 291               | 99   | 6.4% (25/390)   | 4th Gen ELISA | 9.5% (37/390)  | 3rd Gen ELISA | 8.5% (33/390) | 3rd Gen ELISA | –                | –                        | –            | –                | 7.9% (31/390) ELISA |
| Bonja F et al.         | 2015             | Prospective   | Hawassa       | –                | –            | 384          | 258               | 126  | 6.4% (6/384)    | 4th Gen ELISA | 4.8% (16/384)  | –                | –                        | –            | –                | 0.8% (3/384) ELISA |
| Kassu A et al.         | 1995–2002        | Retrospective | Both          | North Gondar     | –            | 11,204       | 10,699             | 545  | 9.9% (109/11204) | ELISA | –                | –                        | –            | –                | –                        | –                 | –                        |
| Rahlenbeck SL et al.   | 1997             | 1994–1995     | Prospective   | Both             | North Gondar | 2186         | 2186              | 0    | 14.5% (317/2186) | ELISA | 14.5% (79/549) | 3rd Gen latex test | –                        | –            | 12.9% (283/2186) RPR |
Table 1 (continued)

| First Author          | Publication year | Sampling year | Study Design | Blood donor type | Setting | Sample size | Blood donor by sex | HIV | HBV | HCV | Syphilis |
|-----------------------|------------------|--------------|--------------|------------------|---------|-------------|-------------------|-----|-----|-----|---------|
| Zewde D et al.        | 1991             | 1989         | Prospective  | Addis Ababa      | HBV     | 408         | –                 | 2.9% (12/408) | –   | 10.8% (44/408) | –   | –       |
| Desie A et al.        | 2007             | 2006         | Prospective  | Bahir Dar       | HBV     | 324         | 283               | 11.7% (38/324) | 2.5% (81/324) | 4th Gen ELISA | 13.3% (43/324) | 1.2% (4/324) | RPR |
| Ramos JM et al.       | 1998–2006        | Both         | Prospective  | West Asir        | HBV     | 3305        | 2754             | 1.5% (51/3305) | –   | –   | –   | –       |
| Ramos JM et al.       | 2008             | 2007–2012    | Retrospective | West Asir       | HBV     | 2606        | –                 | 0.73% (19/2606) | –   | –   | –   | –       |
| sentiens RE et al.    | 2002             | 1991         | Prospective  | Ethiopia         | HBV     | 2610        | 2069             | 7.7% (207/2610) | –   | –   | –   | –       |
| Dro E et al.          | 2004             | 2008         | Prospective  | North Gondar     | HBV     | 600         | 537              | 4.5% (27/600)  | 8.2% (49/600) | 3rd Gen ELISA | 5.8% (35/600) | –   | –       |
| Kabato AA et al.      | 2015             | 2016         | Prospective  | Arba Minch 359   | HBV     | 179         | 162              | –               | 4.7% (17/359) | 3rd Gen ELISA | –   | –       |
| Shiferaw E et al.     | 2014/2015-       | Retrospective | North Gondar | Both             | HBV     | 35,435      | 23,032           | 0.5% (160/35435) | 3.9% (1389/35435)ELISA | 0.6% (203/35435)ELISA | 1.2% (429/35435)ELISA |
|                       | 2017/2018        |              |              |                  |         |             |                  |                 |                 |                 |                     |
| Azeerefegn E et al.   | 2018             | 2015         | Retrospective | Hawassa          | HBV     | 6849        | –                | –               | –               | –               | –       |
| Berhanu S et al.      | 2018             | 2017         | Retrospective | Debre Tabor      | HBV     | 7255        | –                | –               | –               | –               | –       |
| Bisafew Y et al.      | 2018             | 2018         | Prospective  | Debre Markos     | HBV     | 403         | –                | –               | –               | –               | –       |
| Heyredin I et al.     | 2019             | 2019         | Prospective  | Dire Dawa        | HBV     | 500         | –                | –               | –               | –               | –       |
| Assefa A et al 1994   | 1989–1993        | Retrospective | Gondar        | Gondar           | HBV     | 3696        | 3066             | 10.8% (401/3696) | ELISA | –   | –   | –       |
|                       |                  |              |              |                  |         |             |                  |                 |                 |                 |                     |
| Negash M et al.       | 2018             | 2018         | Prospective  | Debre Tabor      | HBV     | 310         | 198              | 2.58% (83/310) | 5.81% (18/310) | 4th Gen ELISA | 4.2%(13/310) | ELISA | –   |
| Tigabu et I           | 2018             | 2018         | Retrospective | Gondar           | HBV     | 5983        | 5118             | 2.9% (147/5983) | 4th Gen ELISA | 4.1%(244/5983) | 3rd gen ELISA | 1.6%(98/5983) | 3rd gen ELISA | –   |

ELISA enzyme linked immunosorbent Assay, gen generation, – represents that the given characteristic is not reported, HBV hepatitis B virus, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, HIV human immunodeficiency virus, RPR rapid plasma regain, TPHA treponema pallidum hemagglutination assay, TTIs transfusion transmissible infections, Both represents the blood donor types are volunteer and replacement type.
Pooled estimates of TTIs

The Pooled estimate and trend of HIV

For the estimation of the pooled prevalence of HIV among blood donors, 34 articles with a total of 355,026 participants’ data were used. These studies reported varying prevalence, ranging from 0.14% to 14.5%. In the random-effect model, the pooled size effect of HIV was 2.83% (95% CI 2.43, 3.23%) (Fig. 2). The trend of HIV showed that the seroprevalence showed a decrement from 1989 to 2018. The random-effects meta-regression analysis also confirmed that the pooled seroprevalence of HIV was negatively but significantly associated with the midpoint year of the data collection period (Coefficient = −0.089; 95% CI −0.133, −0.045; P < 0.001). The seroprevalence estimate of HIV changed from 8.84% (95% CI 5.96, 17.73%) before 2000 to 1.20% (95% CI 0.87, 1.53%) during 2015–2018 (Table 2).

The influential analysis revealed that no single study was outside the 95% CI of the pooled estimate indicating that omitting each study did not affect the pooled estimate. Regarding the publication bias, the visual funnel plot seems symmetric, suggesting that there was no small-study effect. The objective-based test, egger’s statistics, confirmed that there was no small-study effect

| Author                | Year | ES (95% CI) | Weight |
|-----------------------|------|-------------|--------|
| Amhara                | 2016 | 2.51 (1.21, 3.81) | 2.51   |
| Asef F et al          | 2017 | 5.07 (4.63, 5.52) | 3.27   |
| Sharew B et al        | 2018 | 0.23 (0.14, 0.33) | 3.40   |
| Deressa T et al       | 2019 | 3.76 (3.29, 4.22) | 3.26   |
| Tessema B et al       | Unpublished | 0.41 (0.01, 0.80) | 3.30   |
| Biado B et al         | 2017 | 2.15 (1.80, 2.50) | 3.32   |
| Kassu A et al         | 2006 | 9.90 (9.35, 10.45) | 3.20   |
| Rahansele M et al     | 1997 | 14.50 (13.03, 15.98) | 2.33   |
| Desie A et al         | 2007 | 11.73 (8.22, 15.23) | 0.95   |
| Diro E et al          | 2008 | 4.50 (2.84, 6.16) | 2.16   |
| Shiferaw E et al      | 2019 | 0.45 (0.36, 0.52) | 3.41   |
| Berhanu S et al       | 2018 | 0.41 (0.27, 0.56) | 3.39   |
| Assefa A et al        | 1994 | 10.85 (9.85, 11.85) | 2.81   |
| Negash M et al        | 2019 | 2.58 (0.82, 4.35) | 2.06   |
| Tigabu A et al        | 2019 | 2.46 (2.06, 2.85) | 3.30   |
| Subtotal (I-squared = 99.5%, p = 0.000) | | 4.41 (3.50, 5.32) | 42.67 |
| Harar/Dire Dawa       | 2018 | 0.55 (0.42, 0.69) | 3.40   |
| Teklemariam Z et al   | 2018 | 1.24 (0.97, 1.51) | 3.36   |
| Atoz Z et al          | 2018 | 1.40 (0.37, 2.43) | 2.78   |
| Heyredin I et al      | 2019 | 0.98 (0.39, 1.58) | 9.54   |
| Subtotal (I-squared = 90.6%, p = 0.000) | | |  |
| Addis Ababa           | 2005 | 4.17 (2.23, 6.11) | 1.90   |
| Seyoum E et al        | 2018 | 1.64 (0.58, 1.76) | 3.41   |
| Terefe JE et al       | 2018 | 2.95 (1.30, 4.59) | 2.17   |
| Zawde D et al         | 1991 | 2.69 (1.14, 4.24) | 7.48   |
| Subtotal (I-squared = 77.5%, p = 0.012) | | |  |
| South Ethiopia        |      | |  |
| Ambacheh H et al      | 2018 | 1.70 (1.16, 2.23) | 3.21   |
| Berhanselasse M       | 2016 | 1.60 (1.29, 1.91) | 3.34   |
| Biseltig FS et al     | 2016 | 6.41 (3.98, 8.84) | 1.52   |
| Bonja F et al         | 2017 | 1.56 (0.32, 2.53) | 2.57   |
| Azererfeqen E et al   | 2018 | 1.26 (0.99, 1.52) | 3.36   |
| Subtotal (I-squared = 79.8%, p = 0.001) | | |  |
| Tigrai                |      | |  |
| Degefa B et al        | 2018 | 1.03 (0.84, 1.23) | 3.38   |
| Subtotal (I-squared = .%, p = .) | | |  |
| Somalia               |      | |  |
| Abate M et al         | 2016 | 3.16 (2.75, 3.58) | 3.29   |
| Mohamed A et al       | 2016 | 0.14 (0.03, 0.26) | 3.40   |
| Subtotal (I-squared = 99.5%, p = 0.000) | | |  |
| Oromia                |      | |  |
| Kebede W et al        | 2017 | 0.21 (0.13, 0.30) | 3.40   |
| Yemi A et al          | 2017 | 2.13 (1.76, 2.49) | 3.32   |
| Ramos JM et al        | 2008 | 1.54 (1.12, 1.96) | 3.29   |
| Ramos JM et al        | 2016 | 0.73 (0.40, 1.06) | 3.33   |
| Subtotal (I-squared = 97.8%, p = 0.000) | | |  |
| National              |      | |  |
| Sentiers RE et al     | 2002 | 5.94 (5.03, 6.85) | 2.90   |
| Subtotal (I-squared = .%, p = .) | | |  |
| Overall (I-squared = 99.2%, p = 0.000) | | 2.83 (2.43, 3.23) | 100.00 |

NOTE: Weights are from random effects analysis

Fig. 2 Pooled estimate of HIV using random-effect model among blood donors in Ethiopia: a subgroup analysis by region. ES estimated Prevalence of HIV
Since the degree of heterogeneity between the included studies was higher, subgroup analysis was done considering the "region" as a grouping variable. In the random-effects model, the pooled estimated prevalence of HIV was 4.41% (95% CI 3.50, 5.32%) in Amhara region, 1.72% (95% CI 1.18, 2.26%) in South Nations and Nationalities, 1.14% (95% CI 0.22, 2.06%) in Oromia, and 0.98% (95% CI 0.39, 1.58%) in Harar/Dire Dawa (Fig. 2).

**HIV and its association with sex and donor type**

Factors such as sex and donor type were assessed to estimate their effect size on the pooled estimate of HIV. Twenty four and 8 studies had reported the distribution of HIV by sex and donor type, respectively. In the random-effects model, being a replacement blood donor was more likely to have HIV infection among blood donors in Ethiopia (Odds ratio (OR) = 2.09; 95% CI 1.39, 3.13; I-squared = 80.1%) (Fig. 3). However, sex had no association with HIV infection (OR = 1.09; 95% CI 0.85, 1.40; I-squared = 86.1%). In both cases, there was no publication bias as evidenced by egger’s statistics (P > 0.05) and the visual funnel plot.

### The Pooled estimate and trend of HBV

Regarding HBV among blood donors in Ethiopia, 36 articles which include 391, 339 study participants were used for estimation. These studies reported varying prevalence, ranging from 1.03 to 25%. In the random-effects model, the pooled seroprevalence of HBV was 5.20% (95% CI 4.64, 5.77%; with I-squared = 98.4%). The trend analysis also showed that a decrement from 12.03% (95% CI 9.72, 14.34%) before 2000 to 4.30% (95% CI 3.35, 5.24%) during 2015–2018. Though the trend seems to decline from 1986 to 2018, the random-effects metaregression analysis showed that the decline is not significantly associated with the midpoint year of the data collection period (Coefficient = −0.029; 95% CI −0.078, 0.02, P = 0.25) (Table 2). The subgroup analysis revealed that there were considerable variations of HBV estimate across regions in Ethiopia. The visual funnel plot was symmetric, suggesting no publication bias. Likewise, the egger’s statistics showed that there was no small-study effect on the pooled estimate of HBV infection (P = 0.450, coefficient of bias = 1.42) (Fig. 4).

| Study ID | OR (95% CI) | % Weight |
|----------|-------------|----------|
| Degefa B et al (2018) | 1.75 (1.20, 2.54) | 16.68 |
| Teklemariam Z et al (2018) | 1.43 (0.87, 2.35) | 15.04 |
| Gezahgn M et al (2012) | 4.38 (1.71, 11.23) | 9.49 |
| Kebede W et al (2017) | 13.46 (5.53, 32.76) | 10.03 |
| Terefe JE et al (Unpublished) | 2.18 (1.96, 2.43) | 19.22 |
| Ataro Z et al (2018) | 0.20 (0.05, 0.81) | 5.81 |
| Biadgo B et al (2017) | 2.24 (0.82, 6.08) | 8.90 |
| Azerefegn E et al (2018) | 1.51 (0.90, 2.52) | 14.83 |
| Overall (I-squared = 80.1%, p = 0.000) | 2.09 (1.39, 3.13) | 100.00 |

Fig. 3 Effect size of donor type on pooled estimate of HIV using random-effect model

NOTE: Weights are from random effects analysis
**HBV and its association with sex and donor type**  
As there was high-level heterogeneity between the studies included for the estimation of the effect size of sex and donor type on HBV, a random-effects model was fitted. Therefore, male blood donors (OR = 1.87; 95% CI 1.51, 2.32) (Fig. 5), and replacement blood donors (OR = 1.68; 95% CI 1.34, 2.12) (Fig. 6) were more likely to be HBV sero-reactive. Besides, the assessment of publication bias

**Table 2** Trends of the pooled sero-epidemiology of TTIs among blood donors in Ethiopia (1986–2018)

**The trend of pooled sero-prevalence of HIV among blood donors in Ethiopia (1989–2018)**

| Study year (based on mid-term year) | Number of included studies | Total No. of HIV sero-reactive case | Total No. of Population | Pooled prevalence of HIV % (95% CI) | Heterogeneity | Meta-regression (effect of year on HIV prevalence) |
|------------------------------------|-----------------------------|-------------------------------------|-------------------------|-------------------------------------|--------------|--------------------------------------------------|
|                                    |                             |                                     |                         |                                     |              | I² %  | P-value | Coefficient (95% CI) | P-value |
| Before 2000                        | 5                           | 1994                                | 20,103                  | 8.84 (5.96, 17.73)                 | 97.7         |        | <0.001 | −0.089 (−0.133, −0.045) | <0.001 |
| 2000–2004                          | 3                           | 95                                  | 4313                    | 3.27 (1.02, 5.53)                  | 88.5         |        | <0.001 |                               |        |
| 2005–2009                          | 3                           | 296                                 | 9291                    | 4.55 (1.67, 7.44)                  | 98.6         |        | <0.001 |                               |        |
| 2010–2014                          | 11                          | 4197                                | 251,971                 | 1.70 (1.14, 2.26)                  | 99.3         |        | <0.001 |                               |        |
| 2015–2018                          | 12                          | 546                                 | 69,348                  | 1.20 (0.87, 1.53)                  | 94.9         |        | <0.001 |                               |        |
| Total                              | 34                          | 7128                                | 355,026                 | 2.83 (2.43, 3.23)                  | 99.2         |        | <0.001 |                               |        |

**The trend of pooled sero-prevalence of HBV among blood donors in Ethiopia (1986–2018)**

| Study year (based on mid-term year) | Number of included studies | Total No. of HBV sero-reactive case | Total No. of Population | Pooled prevalence of HBV % (95% CI) | Heterogeneity | Meta-regression (effect of year on HBV prevalence) |
|------------------------------------|-----------------------------|-------------------------------------|-------------------------|-------------------------------------|--------------|--------------------------------------------------|
|                                    |                             |                                     |                         |                                     |              | I² %  | P-value | Coefficient (95% CI) | P-value |
| Before 2000                        | 3                           | 173                                 | 1415                    | 12.03 (9.72, 14.34)                 | 46.2         |        | 0.156 | −0.029 (−0.078, 0.02) | 0.25   |
| 2000–2004                          | 2                           | 86                                  | 1200                    | 7.10 (5.14, 9.05)                   | 44.6         |        | <0.001 |                               |        |
| 2005–2009                          | 5                           | 645                                 | 14,985                  | 6.72 (4.03, 9.40)                   | 98.7         |        | <0.001 |                               |        |
| 2010–2014                          | 13                          | 14,652                              | 310,478                 | 4.76 (4.05, 5.47)                   | 98.6         |        | <0.001 |                               |        |
| 2015–2018                          | 13                          | 2240                                | 63,261                  | 4.30 (3.35, 5.24)                   | 96.8         |        | <0.001 |                               |        |
| Total                              | 36                          | 17,796                              | 391,339                 | 5.20 (4.64, 5.77)                   | 98.4         |        | <0.001 |                               |        |

**The trend of pooled sero-prevalence of HCV among blood donors in Ethiopia (1991–2018)**

| Study year (based on mid-term year) | Number of included studies | Total No. of HCV sero-reactive case | Total No. of Population | Pooled prevalence of HCV % (95% CI) | Heterogeneity | Meta-regression (effect of year on HCV prevalence) |
|------------------------------------|-----------------------------|-------------------------------------|-------------------------|-------------------------------------|--------------|--------------------------------------------------|
|                                    |                             |                                     |                         |                                     |              | I² %  | P-value | Coefficient (95% CI) | P-value |
| Before 2000                        | 2                           | 10                                  | 720                     | 1.40 (0.54, 2.26)                   | 0.0          | 1      | 0.014 | −0.041 (−0.093, 0.01) | 0.114  |
| 2000–2004                          | 2                           | 45                                  | 1200                    | 3.69 (−0.36, 7.74)                  | 93.0         | <0.001 |                               |        |
| 2005–2009                          | 4                           | 137                                 | 10,136                  | 1.86 (0.81, 2.90)                   | 95.2         | <0.001 |                               |        |
| 2010–2014                          | 12                          | 3182                                | 306,321                 | 0.71 (0.41, 1.00)                   | 98.7         | <0.001 |                               |        |
| 2015–2018                          | 11                          | 453                                 | 62,499                  | 0.83 (0.55, 1.11)                   | 91.2         | <0.001 |                               |        |
| Total                              | 31                          | 3827                                | 380,876                 | 0.93 (0.73, 1.13)                   | 97.3         | <0.001 |                               |        |

**The trend of pooled sero-prevalence of Syphilis among blood donors in Ethiopia (1989–2018)**

| Study year (based on mid-term year) | Number of included studies | Total No. of Syphilis sero-reactive case | Total No. of Population | Pooled prevalence of Syphilis % (95% CI) | Heterogeneity | Meta-regression (effect of year on Syphilis prevalence) |
|------------------------------------|-----------------------------|-----------------------------------------|-------------------------|-----------------------------------------|--------------|--------------------------------------------------|
|                                    |                             |                                         |                         |                                         |              | I² %  | P-value | Coefficient (95% CI) | P-value |
| Before 2000                        | 3                           | 1334                                    | 23,893                  | 8.39 (3.71, 13.08)                     | 98.8%        | <0.001 | −0.085 (−0.156, −0.015) | 0.021  |
| 2000–2004                          | –                           | –                                       | –                       | –                                      | –            | –      | –                  | –       |
| 2005–2009                          | 4                           | 113                                     | 13,446                  | 0.83 (0.06, 1.59)                     | 96.2%        | <0.001 |                               |        |
| 2010–2014                          | 8                           | 413                                     | 227,743                 | 0.50 (0.29, 0.71)                     | 97.3%        | <0.001 |                               |        |
| 2015–2018                          | 8                           | 614                                     | 55,648                  | 1.04 (0.67, 1.40)                     | 90.8%        | <0.001 |                               |        |
| Total                              | 23                          | 2474                                    | 320,730                 | 1.50 (1.20, 1.80)                     | 99.0%        | <0.001 |                               |        |

* represents that the given characteristic is not reported, CI confidence interval, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, TTIs transfusion transmissible infections
analysis, the pooled estimate of HCV showed a decrement from 1991 to 2018 but not statistically significant (Coefficient = -0.041; 95% CI = -0.093, 0.01; P = 0.114). The pooled estimate changed from 1.40% (95% CI 0.54, 2.26%) before 2000 to 0.83% (95% CI 0.55, 1.11%) during 2015–2018 (Table 2). Egger’s statistics indicated that there was no small-study effect (coefficient of bias = 1.24; P = 0.446). About the effect size of sex and donor type on the pooled estimate of HCV, being a replacement blood donor was significantly associated with HCV (OR = 1.50; 95% CI 1.03, 2.20; I-squared = 75.7%) (Fig. 8). However, sex was not associated with HCV (OR = 1.24; 95% CI 0.95, 1.51). In both factors, there was no evidence of a small-study effect (P > 0.05).

The Pooled estimate and trend of HCV

For the estimation of HCV among blood donors, 31 studies with a total of 380,876 study participants were included. These studies reported varying prevalence, ranging from 0.2% to 13.3%. In the random-effects model, the pooled seroprevalence of HCV was 0.93% (95% CI 0.73, 1.13) (Fig. 7). In the random-effects meta-regression analysis, the pooled estimate of HCV showed a decrement from 1991 to 2018 but not statistically significant

| Author          | Year | ES (95% CI) | Weight |
|-----------------|------|-------------|--------|
| Tsega E et al   | 1987 | 10.89 (8.04, 13.74) | 1.81   |
| Zawde D et al   | 1991 | 10.81 (7.79, 13.83) | 1.71   |
| Rahlenbeck SL et al | 1997 | 14.39 (11.45, 17.33) | 1.76   |
| Gelaw B et al   | 2007 | 6.17 (4.24, 8.09) | 2.40   |
| Diro E et al    | 2008 | 8.17 (5.98, 10.36) | 2.22   |
| Tessema B et al | 2010 | 4.68 (4.17, 5.20) | 3.22   |
| Desie A et al   | 2007 | 25.00 (20.29, 29.71) | 1.01   |
| Assefa A et al  | 2013 | 4.11 (3.31, 4.91) | 3.11   |
| Gezahegn M et al| 2012 | 1.03 (0.71, 1.35) | 3.28   |
| Ramos JM et al  | 2016 | 6.06 (5.05, 7.08) | 3.00   |
| Yemi A et al    | 2011 | 2.08 (1.72, 2.44) | 3.27   |
| Terefe JE et al | Unpublished | 5.05 (4.94, 5.15) | 3.31   |
| Biadgo B et al  | 2017 | 3.46 (3.02, 3.89) | 3.25   |
| Berhanselase M  | 2016 | 4.80 (4.28, 5.33) | 3.22   |
| Teklemariam Z et al | 2018 | 4.39 (4.02, 4.77) | 3.26   |
| Habte Y et al   | 2016 | 3.73 (3.15, 4.30) | 3.20   |
| Degefa B et al  | 2018 | 3.79 (3.43, 4.16) | 3.27   |
| Abate M et al   | 2016 | 9.48 (8.78, 10.17) | 3.16   |
| Ataro Z et al   | 2018 | 4.67 (4.16, 5.19) | 3.22   |
| Hundie GB et al | 2016 | 3.90 (3.74, 4.06) | 3.30   |
| Kebede W et al  | 2017 | 3.06 (2.73, 3.38) | 3.28   |
| Mohammed Y et al| 2016 | 10.89 (9.95, 11.83) | 3.04   |
| Azerefegen E et al | 2018 | 3.43 (3.00, 3.86) | 3.25   |
| Asrie F et al   | 2016 | 3.94 (3.23, 5.56) | 2.81   |
| Biseteg FS et al | 2016 | 9.49 (6.58, 12.40) | 1.77   |
| Bonja F et al   | 2017 | 4.17 (2.17, 6.17) | 2.35   |
| Kabato AA et al | 2016 | 4.74 (2.54, 6.93) | 2.21   |
| Berhanu S et al | 2018 | 2.76 (2.38, 3.13) | 3.26   |
| Deressa T et al | 2018 | 1.22 (0.98, 1.45) | 3.29   |
| Ambachew H et al| 2018 | 4.74 (3.86, 5.62) | 3.07   |
| Shiferaw E et al| 2019 | 3.92 (3.72, 4.12) | 3.30   |
| Tigabu A et al  | 2019 | 4.08 (3.58, 4.58) | 3.23   |
| Birhan W et al  | Unpublished | 3.65 (2.48, 4.82) | 2.90   |
| Biawef Y et al  | 2018 | 4.71 (2.65, 6.78) | 2.30   |
| Heyredin I et al | 2019 | 6.60 (4.42, 8.78) | 2.23   |
| Negash M et al  | 2019 | 5.81 (3.20, 8.41) | 1.95   |
| Overall (I-squared = 98.4%, p = 0.000) | | 5.20 (4.64, 5.77) | 100.00 |

NOTE: Weights are from random effects analysis.
The Pooled estimate and trend of Syphilis

With regard to syphilis, 23 studies comprising 32,073 study participants were eligible for estimating its pooled sero-epidemiology. These studies reported varying prevalence, ranging from 0.1% to 12.9%. In the random-effects model, the pooled estimate of syphilis was 1.50% (95% CI 1.20, 1.80%) (Fig. 9). The pooled estimate declined from 8.39% (95% CI 3.71, 13.08%) before 2000 to 1.04% (95% CI 0.67, 1.40%) during 2015–2018. The trend analysis showed a decrement from 1989 to 2018. This has been supported by the random-effects meta-regression analysis, and the analysis confirmed that the pooled seroprevalence of Syphilis was negatively but significantly associated with the midpoint year of the data collection period (Coefficient = −0.085; 95% CI −0.156, −0.015; $P = 0.021$) (Table 2).
As there was a publication bias evidenced by egger’s statistics (P < 0.001), Duval and Tweedie’s trim and fill analysis was done to adjust the final pooled estimate of syphilis sero-epidemiology. For the adjustment of an estimate, 12 studies were filled, and it was found that the pooled estimated prevalence in the random-effects model was found to be 0.11% (95% CI 0.061, 0.19%).

Concerning the effect size of sex and donor type on the sero-epidemiology of syphilis, being a male blood donor was more likely to be sero-reactive for syphilis compared to being a female donor in the random-effects model (OR = 1.35; 95% CI 1.01, 1.79; I-squared = 68%) (Fig. 10). Unlike sex, donor type was not associated with syphilis sero-reactivity (OR = 1.84; 95% CI 0.56, 6.07; I-squared = 88.4%). No publication bias was observed for both factors (P > 0.05).

### Discussion

Blood donation is becoming one of the lifesaving emergency services in medical and obstetrics services. Despite its advantage in lifesaving practice, blood transfusion is a potential risk for transmission of TTIs, such as HBV, HIV, HCV and syphilis [72]. In this review, the pooled sero-epidemiology of HBV, HIV, HCV and syphilis among blood donors in Ethiopia was 5.20% (95% CI 4.64, 5.77%), 2.83% (95% CI 2.43, 3.23%), 0.93% (95% CI 0.73, 1.13%) and 1.50% (95% CI; 1.20, 1.80%), respectively. The pooled sero-epidemiology of HBV was higher than the estimates of a systematic review conducted in Iran (0.7%) [73], Eastern Mediterranean and Middle Eastern Countries (2.03%) [74] and European countries (0.74%) [75]. The possible reasons for the observed discrepancy might be due to the differences in cultural practices with regard to prevention of TTIs, and economic status which results in variation in vulnerability for sexually transmitted diseases. In addition, variation

| Study ID | OR (95% CI) | Weight |
|----------|-------------|---------|
| Habte Y et al (2016) | 1.76 (1.13, 2.73) | 10.12 |
| Degefa B et al (2018) | 1.16 (0.95, 1.41) | 14.48 |
| Teklemariam Z et al (2018) | 1.27 (1.06, 1.53) | 14.75 |
| Kebede W et al (2017) | 2.96 (2.33, 3.75) | 13.84 |
| Terefe JE et al (Unpublished) | 1.49 (1.41, 1.58) | 16.13 |
| Ataro Z et al (2018) | 0.96 (0.66, 1.39) | 11.40 |
| Biadgo B et al (2017) | 2.93 (1.20, 7.16) | 4.67 |
| Bonja F et al (2017) | 12.50 (2.41, 64.82) | 1.72 |
| Azerefegn E et al (2018) | 2.23 (1.67, 2.98) | 12.90 |
| Overall (I-squared = 87.2%, p = 0.000) | 1.68 (1.34, 2.12) | 100.00 |

NOTE: Weights are from random effects analysis

![Fig. 6 Effect size of donor type on pooled estimate of HBV using random-effect model](image-url)
in the time period, the strength of preliminary screening of donors and factors related to testing algorithms used for screening might also be the possible reason for the discrepancy in the sero-epidemiology of HBV.

Moreover, our review showed that male blood donors (OR = 1.87; 95% CI 1.51, 2.32) were more likely to be HBV sero-reactive than females. This was in line with previously established studies in south Iran [76], Philippines [77], Ghana [78] and Egypt [79]. Another study
also reported that females were less likely to be positive for HBV [80]. Almost 95% of HBV infected persons clear HBV by developing a protective Hepatitis B Surface Antibody (HBsAb) when HBV infection is acquired during adulthood, and only 5 to 10% of HBV infected persons will develop a persistent infection. Particularly, due to the slower plasma extinction rate in males, males are about 1.5 times more likely to develop chronic HBV infection relative to females, suggesting that sex is one of the genetic determinants that affect disease outcome [81]. On the other hand, replacement blood donors (OR = 1.68; 95% CI 1.34, 2.12) were more likely to be HBV sero-reactive compared to volunteer blood donors. This result was supported by earlier studies in which the reported prevalence of HBV among replacement donors was higher than that of voluntary donors [82, 83]. This could be the fact that during replacement donation, the donor might not consider the details of all his/her previous risky behaviours for TTIs as compared to volunteer donors.

Similarly, the pooled sero-epidemiology of HIV was higher than the estimate done in Iranian blood donors (0.0079%) [1]. The possible reasons for this difference might be attributable to the type of donors’ recruited (volunteer versus replacement), and the testing algorithms and kits used to diagnose HIV. In addition, the discrepancy was explained by the variation of the study period in which studies included for the estimation, as the Iranian included studies published since 1996, whereas our estimate included studies published since 1989.

Regarding factors associated with HIV, our review showed that being a replacement blood donor was more likely to have HIV infection compared to volunteer donors (OR = 2.09; 95% CI 1.39, 3.13). A consistent result had been reported previously in different countries [82, 83]. This might be partly explained by that, during replacement blood donation, family members of blood donors may not pass through strict preliminary screening as a result of the emergency nature of the case. Nevertheless, the prevalence of HIV was not significantly associated with sex. But other studies reported that the prevalence was high among males than females in the South of Iran [1, 76]. On the other hand, a study conducted in Iran in 2017 revealed that the seroprevalence of HIV among females was high [84]. This discrepancy in HIV report in terms of gender could be due to differences in the age status of employed donors and risky personal behaviours.

The pooled sero-epidemiology of HCV was 0.93% (95% CI 0.73, 1.13%). This estimate was consistent with
estimates of first-time blood donors from European countries (0.02–3.3%). Our estimate is lower than an estimated prevalence of HCV Chinese blood donors (8.6%) [85]. The plausible reasons for the difference might be due to; firstly, the variation in the method of diagnosis, for example, the systematic review done in China included studies that used molecular techniques; secondly, the difference in population phenomena between countries like population migration, and thirdly, the difference in practices related to safe sexual practice. In addition, one of the major reasons for the variation in HCV prevalence is probably related to different safety regulations and variations in the level to which they are reinforced across countries (Additional file 1: Table S1, Additional file 2: Table S2).
HCV was significantly associated with donor type. Replacement donors were 1.5 times more likely to be HCV sero-reactive compared to volunteer donors (OR = 1.50; 95% CI 1.03, 2.20). This might be probably because volunteer blood donors donate blood in a regular manner who know their sero-status for HCV infection before donating blood. Thus, volunteer blood donors were found to be relatively safer than replacement donors in which blood banks should follow stringent donor selection criteria with an emphasis on getting more volunteer blood donors. However, sex was not associated with HCV in this study.

Based on our review, the prevalence of syphilis was 1.50% (95% CI 1.20, 1.80%). This was almost consistent with the previous report from Kenya 1.0% [86]. On the other hand, a higher prevalence of syphilis was reported from Burkina Faso 3.96% [10] and Nigeria 4.2% [87]. In contrast to the current finding, a lower prevalence of syphilis was reported from earlier studies in Pakistan.
0.43% [88] and India 0.43% [89]. The possible reason for the difference in the magnitude of syphilis across studies may be due to variation in risk behaviours in different geographical locations, or partly due to differences in socio-cultural practices.

On the other hand, male blood donors were more likely to be sero-reactive for syphilis (OR = 1.35; 95% CI 1.01, 1.79) compared to female donors. This might be due to differences in gender-related practices such as having multiple sexual partners. In addition, alcohol abuse is common among males that might expose males to high-risk behaviour which could attribute to an increased in the prevalence of syphilis. Furthermore, in some countries including Ethiopia, males make up the majority of blood donors. This could potentially be one factor as to why males had a higher odds ratio than females for TTIs. In this review, from the total 45 studies included in the review, 36 reported donor distribution by sex, and males accounted for 76.83% (324,590/422,499) of blood donors.

Conclusion
In this systematic review, the pooled estimate of HBV, HIV, HCV and syphilis was high suggesting that there is a need to design and implement strategies to reduce the burden of TTIs in the general population. Moreover, creating community awareness about the prevention of TTIs should be strengthened. Moreover, being a replacement donor was also associated with high HBV, HIV and HCV infection. In addition, advanced and vigilance screening techniques of donated blood should be strengthened prior to transfusion. Furthermore, national policies and strategies of post-donation counselling for recruitment and retention of safe regular donors are a timely need. Lastly, conducting a national population-based survey for TTIs has of utmost importance to monitor the burden and trend of TTIs in the community.

The review has some limitations. One of the limitations is a high level of heterogeneity between included studies which can be attributed to differences in methodology, study period, and geographic location. Besides, there were differences in the diagnostic methods used across the studies which might be implicated with a high level of heterogeneity. Given these limitations, the review was conducted according to the preferred reporting items for systematic review and meta-analysis (PRISMA-P 2015 statement) protocol. Besides, a comprehensive searching of databases and the involvement of experts improved the quality of evidence generated.

Abbreviations
FMoH: Federal Ministry of Health; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; OR: Odds ratio; TTI: Transfusion transmitted infection; WHO: World Health Organization.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-021-06505-w.

Acknowledgements
The authors would like to acknowledge the College of Medicine and Health Sciences, the University of Gondar for infrastructure support to conduct this systematic review. Besides, we are grateful to the authors of the studies included in this systematic review.

Authors' contributions
MM, ES, MA, BB, SA, BW, and DG were involved in the design, literature searching, and assessment of study quality and data extraction. BE, ZA, BT, TD, DD, AK and TT revised the quality of literature. MM, ES, BW, DG, BT, BB, AK, and MA performed the statistical analysis and drafted the manuscript. All the authors read and approved the final manuscript.

Funding
The authors received no specific funding for this work.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declared that there is no competing interests.

Author details
1 Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. 2 Department of Clinical Chemistry, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. 3 Department of Human Nutrition, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. 4 Ethiopian Institute of Public Health, Addis Ababa, Ethiopia. 5 Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. 6 Department of Medical
Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. 7Department of Surgical Nursing, School of Nursing, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Received: 20 August 2019  Accepted: 30 July 2021
Published online: 09 August 2021

References

1. Musavi H, Rahimi H, Kooti W, Dorostkar R, Azami M, Sharghi M, Ashrafizadeh H, Firouzbakht M, Taheri RA. Prevalence of human immunodeficiency virus in Iranian blood donors: a systematic review and meta-analysis. Arch Iran Med. 2018;21(6):260–7.

2. Patel PA, Patel SP, Oza HV. Seroprevalence of transfusion transmitted infections (TTIs) in blood donors at western Ahmedabad-A secondary care hospital based study. Int J Biomed Res. 2012;3(2):1806–10.

3. Azerfeignon E, Worku M, Hailemariam M. Transfusion-transmissible infections among blood donors at Hawassa Regional Blood Bank Center, South Ethiopia. JIRSMB. 2018;4(3):10–6.

4. WHO. Global Status Report on Blood Safety and Availability 2016. 2017. File: WHO. 2016.

5. Jayaraman S, Chalabi Z, Perel P, Guerrero C, Roberts I. The risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion. 2010;50(2):433–42.

6. Fasola FA, Otegbayo IA. Post-transfusion viral hepatitis in sickle cell anemia: retrospective-prospective analysis. Niger J Clinical Practice. 2002;5(1):16–9.

7. WHO. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 ISO. [https://www.who.int/publications/item/global-hepatitis-report-2017].

8. Sonderup MW, Afthene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Lohouëts-Kouacou M-J, Lam P. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030. The Lancet Gastroenterol Hepatol. 2017;2(12):910–9.

9. Mora N, Adams WH, Kliethermes S, Dugas L, Balasubramanian N, Sandhu J, Nde H, Small C, Jose J, Scaglione S. A synthesis of hepatitis C prevalence estimates in Sub-Saharan Africa. 2000–2013. BMC Infect Dis. 2016;16(1):283.

10. Nagalo MB, Sanou M, Bisseye C, Kabore MI, Nebiye YK, Kienou K, Jobo A, Dahourou H, Ouatata S, Zongo JD, et al. Seroprevalence of human immunodeficiency virus, hepatitis B and C viruses and syphilis among blood donors in Koudougou (Burkina Faso) in 2009. Blood Transfus. 2011;9(4):419–24.

11. Bisseye C, Eko Mba JM, Ntame Ngondo NM, Kossoue HE, Butterfield RJ, Mombo LE, Mbatchi B, Torremat B, Nagalo BM, Allain JP. Decline in the seroprevalence of syphilis markers among first-time blood donors in Libreville (Gabon) between 2004 and 2016. BMC Public Health. 2019;19:167.

12. Jary A, Dienta S, Leducu V, Le Hingarat Q, Cisse M, Diarra AB, Fofana DB, Ba A, Baby M, Achenbach CJ, et al. Serorelevance and risk factors for HIV, HCV, HBV and syphilis among blood donors in Mali. BMC Infect Dis. 2019;19:1064.

13. Tesseram B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, Emmrich F, Sack U. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis. 2019;10:111.

14. WHO. Blood Safety in Ethiopia, WHO Regional office for Africa 2014. [http://www.afro.who.int/en/ethiopia/country-programmes/topics/4466-blood-safety.html]. Accessed date: 28/2/2019.

15. FMoH: Federal Democratic Republic of Ethiopia Ministry of Health. National Blood Transfusion Services Strategy 2005. [http://www.transplantobservatory.org/download/national-blood-transfusion-services-strategy-2005-ethiopia/]

16. Belyhun Y, Maier M, Mulu A, Diro E, Liebert UG. Hepatitis viruses in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:761.

17. Mulugeta H, Dessie G, Wagenf E, Jara D, Leshargie CT, Negesse A. Seroprevalence and trend of human immunodeficiency virus among blood donors in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2019;19:383.

18. Shamseddin LW, Hofer D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.

19. JBI. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews: Checklist for Analytical Cross Sectional Studies 2016. [http://joannabriggs.org/research/critical-appraisal-tools.html]. Accessed date: 14 March 2019.

20. Munn Z, Moola S, Lisy K, Ritano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.

21. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(16):1539–58.

22. DeSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

23. Tweedie R, Duval S. A nonparametric, “Trim andFill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc. 2000;95:89–98.

24. Gebreselassie L. Occurrence of hepatitis B surface antigen and its antibody in Ethiopian blood donors. Ethiop Med J. 1983;21(4):205–8.

25. Gebreselassie L. The distribution of the subtypes of HBsAg in Ethiopia. Int J Epidemiol. 1986;15(3):392–4.

26. Huny K, Kassu A, Mulu A, Worku N, Fetene T. Seroprevalence and risk factors for hepatitis B virus infection in the healthy blood donors at Jimma University Hospital, Southwest Ethiopia. Pharmacologyonline 2008;3(32–7).

27. Tsegaye E, Mengesha B, Nordenfelt E, Hansson BG, Lindberg J. Serological survey of human immunodeficiency virus infection in Ethiopia. Ethio Med J. 1988;26(6):179–84.

28. Dessie A, Abraha B, Walle F, Welday D, Tamene W. Evaluation of determine HIV-1/2 rapid diagnostic test by 4th generation ELISA using blood donors’ serum at Felege Hiwot Referral Hospital, northwest Ethiopia. Ethiop Med J. 2008;46(1):1–5.

29. Dessie A, Abraha B. Seroprevalence of major blood-borne infections among blood donors at Felege Hiwot referral hospital, northwest Ethiopia. Ethiop J Health Dev. 2007;21(1):68–9.

30. Terefe JE, Tsegaye A, Tamene M, G/Michael D, Zeleke A. Assessment of transfusion transmissible infections among blood donors (six years study) and strategy on direct laboratory testing cost of blood screening at national blood transfusion service of Addis Ababa, Ethiopia. [Unpublished article].

31. Birhan W, Deserra T, Enawang B, Abebe M, Wondiferaw W, Terefe B, Melku M. Distribution of transfusion-transmissible infection among apparently healthy blood donors in Amhara regional state, North-West, Ethiopia: Cross sectional study. [Unpublished article].

32. Asse F, Kifle H, Gebremedhin T. Magnitude of transfusion-transmissible infections among blood donors at North Gonder Blood Bank, northwest Ethiopia. Ethiop J Lab Med. 2016;3(3):44–53.

33. Teklemanaz Z, Mitiku H, Weldegebrel F. Seroprevalence and trends of transfusion transmitted infections at Harar blood bank in Harari regional state, Eastern Ethiopia: eight years retrospective study. BMC Hematol. 2018;18:24.

34. Habte Y, Seyoum B, Alemayehu T. Hepatitis B virus infection and associated factors among blood donors at Dire Dawa, Eastern Ethiopia. J Antivir Antiretrovir. 2016;8(4):103–6.

35. Deressa T, Birhan W, Enawang E, Abebe M, Baynes HW, Desta M, Terefe B, Melku M. Proportion and predictors of transfusiontransmissible infections among blood donors in North Shewa Zone, Central North Ethiopia. PLoS ONE. 2018;13(3):0194083.

36. Ambachew H, Zheng M, Pappoe F, Shen J, Xu Y. Genotyping and seroepidemiological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia. PLoS ONE. 2018;13(2):0193177.

37. Degefa B, Gebreyesus T, Gebremedhin Z, Melkamu G, Gebrekidan A, Hallekios T, Tsegay E, Niguse S, Abdulkader M. Prevalence of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: a three-year retrospective study. J Med Virol. 2018;90(11):1724–9. [https://doi.org/10.1002/jmv.25248].
38. Abate M, Wolde T. Seroprevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and syphilis among Blood Donors at Jigjiga Blood Bank, Eastern Ethiopia. Ethiop J Health Sci. 2016;26(2):153–60.
39. Gelaw B, Mengstus Y. The prevalence of HBV, HCV and malaria parasites among blood donor in Amhara and Tigray regional states. Ethiop J Health Dev. 2008;22(1):13–7.
40. Gezahien M, Woldemicheal K, Godesso A. HIV sero-prevalence trend among blood donors in Jimma University Specialized Hospital, South-west Ethiopia. Ethiop J Health Sci. 2011;21(2):37–43.
41. Hundie GB, Raj VS, Gebremichael D, Haagmans BL. Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia. J Med Virol. 2017;89(7):1300–3.
42. Kebede W, Mekonnen Z, Gerbi A, Abebe G. Transfusion-transmissible infection surveillance among blood donors in South-west Ethiopia: a six years retrospective study. Asian Pac J Trop Dis. 2017;7(3):156–61.
43. Yami A, Alemseged F, Hasien A. Hepatitis B and C viruses infections and their association with Human Immunodeficiency virus: a cross-sectional study among blood donors in Ethiopia. Ethiop J Health Sci. 2011;21(1):67–75.
44. Tsega E, Mengesha B, Nordenfelt E, Hansson BG, Lindberg J. Prevalence of hepatitis B virus markers among Ethiopian blood donors: is HBAg screening necessary? Trop Geogr Med. 1987;39(4):336–40.
45. Aitaro Z, Urgessa F, Wasihun T. Prevalence and trends of major transfusion transmissible infections among blood donors in Dire Dawa Blood bank, Eastern Ethiopia: retrospective study. Ethiop J Health Sci. 2018;28(6):701–7.
46. Mohammed Y, Bekele A. Seroprevalence of transfusion transmitted infection among blood donors at Jigjiga blood bank, Eastern Ethiopia retrospective 4 years study. BMC Res Notes. 2016;9:129.
47. Assela A, Mathewos B, Alemu A, Addis Z, Alem M, Gazachew M. Hepatitis B and C viral infections among blood donors at Bahir dar, Ethiopia. Int J Med Res Heal Sci. 2013;2(3):624–30.
48. Blagod B, Shiferaw E, Woldu B, Alene KA, Melku M. Transfusion-transmissible viral infections among blood donors at the North Gondar district blood bank, northwest Ethiopia: a three year retrospective study. PLoS ONE. 2017;12(7):e0180416.
49. Birhaneselasse M. Prevalence of transfusion-transmissible infections in donors to an Ethiopian Blood Bank between 2009 and 2013 and donation factors that would improve the safety of the blood supply in underdeveloped countries. Lab Med. 2016;47(2):134–9.
50. Botegeen FS, Bekele FB, Ageru TA, Wada FW. Transfusion-transmissible infections among voluntary blood donors at Wolaita Sodo University Teaching Referral Hospital, South Ethiopia. Can J Infect Dis Med Microbiol. 2016;2016:8254343.
51. Bonfa F, Hussein M, Alemu J, Gemechu G, Birhaneselasse M. The prevalence of transfusion transmitted infections: a focus on hepatitis B virus among blood donors at Hawassa blood bank center, Southern Ethiopia. Int J Blood Transfus Immunohaematol. 2017;7:7–14.
52. Rahlenbeck SI, Yahannes G, Molla K, Reifen R, Assefa A. Infection with HIV, syphilis and hepatitis B in a survey of blood donors. Int J STD AIDS. 1997;8(4):261–4.
53. Zawde D, Siray Y. National blood requirement, serum ALT and hepatitis C virus infection among voluntary blood donors in Wolaita Sodo University Hospital, Ethiopia. Br J Haematol. 2013;164(2):274–8.
54. Ramos JM, Tissiano G, Fano H, Yohannes T, Gosa A, Reyes F, Gergdolas M. Prevalence of positive HIV, HBV, HCV and treponemal tests in blood donors in a rural hospital in southern Ethiopia. J Clin Virol 2016; 77(60–2).
55. Dine D, Alemu S, Abebaw S, Woldu B, Alene KA, Melku M. Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: a four years retrospective study. Health Care Curr Rev. 2018;6:4.
56. Bialfrew Y, Hallu G, Samuel T. Prevalence and associated factors of hepatitis B virus infection among blood donors in Debre Markos Blood Bank Centre, Northwest Ethiopia, 2018. Epidemiology (Sunnyvale). 2018;8:4.
57. Heyredin I, Mengistie B, Weldegebrael F. Sero-prevalence of transfusion transmissible infections and associated factors among blood donors in Eastern Ethiopia: an institutional-based cross-sectional study. SAGE Open Med. 2019;7:1–8.
58. Negash M, Ayalew M, Geremew D, Workineh M. Seroprevalence and associated risk factors for HIV, hepatitis B and C among blood donors in South Gondar District blood bank, Northwest Ethiopia. BMC Infect Dis. 2019;19:430.
59. Tigabu A, Erguda T, Mekonnen F. Seroprevalence of transfusion transmissible viral infections (HIV, HBV and HCV) among voluntary blood donors at University of Gondar Comprehensive Specialized Hospital, Gondar; Northwest Ethiopia. BMC Infect Dis. 2019;19:393.
60. Sharew B, Mulu A, Tekla B, Tesfaye T. HIV-Sero-prevalence trend among blood donors in North East Ethiopia. Afr Health Sci. 2017;27(3):72–8.
61. Seyoum E, Walday D, Mekonnen T, Germa M, Meselie T, Kallander C, Gronowitsz S, Britton S. Alternative approach to blood screening using the ExaVir reverse transcriptase activity assay. Curr HIV Res. 2005;3(4):371–6.
62. Kassu A, Mofges F, Mekonnen F, Mengistu G, Abate E, Mekonnen E, Molla K, Zeidwe T, Asefa E, Wondimu Y, et al. Seroprevalence of human immunodeficiency virus among blood donors in Northwest Ethiopia, 1993–2005. Trop Doct. 2010;40(4):106–7.
63. Ramos JM, Reyes F, Tesfamanam A. Seroprevalence of human immunodeficiency virus among blood donors in a rural Ethiopian hospital. Trop Doct. 2008;38(3):182–3.
64. Sentjens RE, Siray Y, Vnelink H, Kebede D, Ader HJ, Leckie G, Reesink HW. Prevalence of and risk factors for HIV infection in blood donors and various population subgroups in Ethiopia. Epidemiol Infect. 2002;128(2):221–8.
65. Assefa A, Rahlenbeck S, Molla K, Alemu S. Sero-prevalence of HIV-1 and syphilis antibodies in blood donors in Gonder, Ethiopia, 1989–1993. J Acquir Immune Defic Syndr. 1994;7(12):1282–5.
66. Frommel D, Tekle-Haimanot R, Berhe N, Assuel L, Verder M, Preux PM, Denis F. A survey of antibodies to hepatitis C virus in Ethiopia. Am J Trop Med Hyg. 1993;49(6):435–9.
67. Tsega E, Nordenfelt E, Hansson BG. Hepatitis C virus infection and chronic liver disease in Ethiopia where hepatitis B infection is hyperendemic. Trans R Soc Trop Med Hyg. 1995;89(2):171–4.
68. Siray Y, Tegene Y. Prevalence of syphilis among Ethiopian blood donors. Ethiop J Health Dev. 1995;9(1):91103.
69. Garraud O, Filho LA, Laperche S, Tayou-Tagny C, Pozzetto B. The infectious risks in blood transfusion as of today—a no black and white situation. Presse Med. 2016;45(7–8 Pt 2):303-311.
70. Alizadeh S, Pakzad I, Sayehmiri K, Pakzad R, Darshini P. Prevalence of hepatitis B among blood donors in Iran: a systematic review and meta-analysis. Asian J Biol Sci. 2014;7(2):35–46.
71. Babanejad M, Izadi N, Najafi F, Alavian SM. The HBsAg prevalence among blood donors from eastern Mediterranean and middle eastern countries: a systematic review and meta-analysis. Hepat Mon. 2016;16(3):35664.
72. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar MW. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis. 2013;13:181.
73. Farhadipour F, Taherkhani R, Tajbaksh S, Tangestani MG, Hajiani G, Sharifi N, Taherkhani S, Nejadmolkhey K. Prevalence and trends of transfusion-transmissible viral infections among blood donors in south of Iran: an Eleven-Year retrospective study. PLoS ONE. 2016;11(6):0157615.
74. Yanase Y, Ohida T, Kaneita Y, Agdamag DMD, Leaño PS, Gill CJ. The prevalence of HIV, HBV and HCV among Filipino blood donors and overseas work visa applicants. Bull World Health Organ. 2007;85(2):131–7.
75. Walana W, Ahiaba S, Hokey F, Vicar EK, Ader HJ, Leckie G, Reesink HW. Hepatitis C virus infection and chronic liver disease in Ethiopia where hepatitis B infection is hyperendemic. Trans R Soc Trop Med Hyg. 1995;89(2):171–4.
76. Anikwasi NKT, Arwawat K. Risk factors of acute blood transfusion reactions in pediatric patients in Sanglah General Hospital, Bali-Indonesia. Med J. 2016;7(35):534–8.
81. Thursz MR. Host genetic factors influencing the outcome of hepatitis. J Viral Hepat. 1997;4(4):215–20.
82. Bhawani Y, Rao PR, Sudhakar V. Seroprevalence of transfusion transmissible infections among blood donors in a tertiary care hospital of Andhra Pradesh. Biol Med. 2010;2(4):45–8.
83. Shah N, Shah J, Jhaveri P, Patel K, Shah C, Shah N. Seroprevalence of HBV, HCV, HIV, and syphilis among blood donors at a tertiary care Teaching Hospital in Western India. Gujarat Med J. 2013;68(2):35–9.
84. Zadsar M, Pourfathollah AA, Rasooli M, Karimi G. Trends and sero-epidemiology of human immuno deficiency virus in voluntary blood donations in Iran, 2008–2013. Arch Iran Med. 2017;20(3):135–40.
85. Gao X, Cui Q, Shi X, Su J, Peng Z, Chen X, Lei N, Ding K, Wang L, Yu R, et al. Prevalence and trend of hepatitis C virus infection among blood donors in Chinese mainland: a systematic review and meta-analysis. BMC Infect Dis. 2011;11:88.
86. Mahuro GM, Gichangi PB, Mwangi CW, Kipkorir N. Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency virus and syphilis in donated blood in Kenya, 2016: situation analysis. J Blood Disord Transfus. 2017;8(4):1000389.
87. Okorovu RU, Okafor IM, Asenit N, Okpokam DC. Seroprevalence of transfusion-transmissible infections (HBV, HCV, syphilis and HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation. BMC Public Health. 2018;18:645.
88. Attaullah S, Khan S, Khan J. Trend of transfusion transmitted infections frequency in blood donors: provide a road map for its prevention and control. J Transl Med. 2012;10:20.
89. Makrro RN, Hegde V, Chowdhry M, Bhatia A, Rosamma NL. Seroprevalence of infectious markers & their trends in blood donors in a hospital based blood bank in north India. Indian J Med Res. 2015;142(4):317–22.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.